Takeda Pharmaceutical (TAK) Land & Improvements (2017 - 2019)

Takeda Pharmaceutical's Land & Improvements history runs 3 years deep, the most recent figure standing at $312.1 million for Q1 2019.

• On a quarterly basis, Land & Improvements changed N/A year-over-year to $312.1 million in Q1 2019; TTM through Mar 2019 was $312.1 million, a N/A change from a year earlier, with the FY2019 full-year figure at $312.1 million, changed N/A from the prior year.
• Land & Improvements advanced to $312.1 million in Q1 2019 per TAK's latest filing, from $295.6 million in the prior quarter.
• Across five years, Land & Improvements topped out at $332.3 million in Q4 2017 and bottomed at $295.6 million in Q4 2018.
• The 3-year median for Land & Improvements is $312.1 million (2019), against an average of $313.3 million.
• Biggest YoY gain for Land & Improvements was 11.04% in 2018; the steepest drop was 11.04% in 2018.
• Year by year, Land & Improvements stood at $332.3 million in 2017, then fell by 11.04% to $295.6 million in 2018, then gained by 5.6% to $312.1 million in 2019.
• Per Business Quant, the three latest TAK Land & Improvements figures stand at $312.1 million (Q1 2019), $295.6 million (Q4 2018), and $332.3 million (Q4 2017).